126 related articles for article (PubMed ID: 25884720)
1. COP1, the negative regulator of ETV1, influences prognosis in triple-negative breast cancer.
Ouyang M; Wang H; Ma J; Lü W; Li J; Yao C; Chang G; Bi J; Wang S; Wang W
BMC Cancer; 2015 Mar; 15():132. PubMed ID: 25884720
[TBL] [Abstract][Full Text] [Related]
2. miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer.
Li J; Lai Y; Ma J; Liu Y; Bi J; Zhang L; Chen L; Yao C; Lv W; Chang G; Wang S; Ouyang M; Wang W
BMC Cancer; 2017 Nov; 17(1):745. PubMed ID: 29126392
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers.
Bayoglu IV; Kucukzeybek BB; Kucukzeybek Y; Varol U; Yildiz I; Alacacioglu A; Akyol M; Demir L; Dirican A; Yildiz Y; Salman T; Tarhan MO
Biomed Pharmacother; 2015 Mar; 70():190-5. PubMed ID: 25776500
[TBL] [Abstract][Full Text] [Related]
4. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
[TBL] [Abstract][Full Text] [Related]
5. COP1 is downregulated in renal cell carcinoma (RCC) and inhibits the migration of RCC ACHN cells in vitro.
Ta L; Xuan C; Xing N; Zhu X
Mol Med Rep; 2016 Aug; 14(2):1371-8. PubMed ID: 27278120
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases.
Zhang Y; Dai J; McNamara KM; Bai B; Shi M; Chan MS; Liu M; Sasano H; Wang X; Li X; Liu L; Ma Y; Cao S; Xing Y; Zhao B; Song Y; Wang L
BMC Cancer; 2015 Oct; 15():699. PubMed ID: 26472563
[TBL] [Abstract][Full Text] [Related]
7. COP1 is a tumour suppressor that causes degradation of ETS transcription factors.
Vitari AC; Leong KG; Newton K; Yee C; O'Rourke K; Liu J; Phu L; Vij R; Ferrando R; Couto SS; Mohan S; Pandita A; Hongo JA; Arnott D; Wertz IE; Gao WQ; French DM; Dixit VM
Nature; 2011 May; 474(7351):403-6. PubMed ID: 21572435
[TBL] [Abstract][Full Text] [Related]
8. KLF4 and NANOG are prognostic biomarkers for triple-negative breast cancer.
Nagata T; Shimada Y; Sekine S; Moriyama M; Hashimoto I; Matsui K; Okumura T; Hori T; Imura J; Tsukada K
Breast Cancer; 2017 Mar; 24(2):326-335. PubMed ID: 27300169
[TBL] [Abstract][Full Text] [Related]
9. Transforming growth factor-β, insulin-like growth factor I/insulin-like growth factor I receptor and vascular endothelial growth factor-A: prognostic and predictive markers in triple-negative and non-triple-negative breast cancer.
Bahhnassy A; Mohanad M; Shaarawy S; Ismail MF; El-Bastawisy A; Ashmawy AM; Zekri AR
Mol Med Rep; 2015 Jul; 12(1):851-64. PubMed ID: 25824321
[TBL] [Abstract][Full Text] [Related]
10. CIP4 promotes metastasis in triple-negative breast cancer and is associated with poor patient prognosis.
Cerqueira OL; Truesdell P; Baldassarre T; Vilella-Arias SA; Watt K; Meens J; Chander H; Osório CA; Soares FA; Reis EM; Craig AW
Oncotarget; 2015 Apr; 6(11):9397-408. PubMed ID: 25823823
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of miR-301a correlates with poor prognosis in triple-negative breast cancer.
Yu H; Li H; Qian H; Jiao X; Zhu X; Jiang X; Dai G; Huang J
Med Oncol; 2014 Nov; 31(11):283. PubMed ID: 25311065
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
Choi JE; Kang SH; Lee SJ; Bae YK
Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
[TBL] [Abstract][Full Text] [Related]
13. MAPKAP kinase 2 overexpression influences prognosis in gastrointestinal stromal tumors and associates with copy number variations on chromosome 1 and expression of p38 MAP kinase and ETV1.
Birner P; Beer A; Vinatzer U; Stary S; Höftberger R; Nirtl N; Wrba F; Streubel B; Schoppmann SF
Clin Cancer Res; 2012 Apr; 18(7):1879-87. PubMed ID: 22351694
[TBL] [Abstract][Full Text] [Related]
14. Endocan as a prognostic biomarker of triple-negative breast cancer.
Sagara A; Igarashi K; Otsuka M; Kodama A; Yamashita M; Sugiura R; Karasawa T; Arakawa K; Narita M; Kuzumaki N; Narita M; Kato Y
Breast Cancer Res Treat; 2017 Jan; 161(2):269-278. PubMed ID: 27888420
[TBL] [Abstract][Full Text] [Related]
15. E1A-mediated inhibition of HSPA5 suppresses cell migration and invasion in triple-negative breast cancer.
Chen HA; Chang YW; Tseng CF; Chiu CF; Hong CC; Wang W; Wang MY; Hsiao M; Ma JT; Chen CH; Jiang SS; Wu CH; Hung MC; Huang MT; Su JL
Ann Surg Oncol; 2015 Mar; 22(3):889-98. PubMed ID: 25212833
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of PIK3CA protein expression in triple negative breast cancer and its subtypes.
Elfgen C; Reeve K; Moskovszky L; Güth U; Bjelic-Radisic V; Fleisch M; Tausch C; Varga Z
J Cancer Res Clin Oncol; 2019 Aug; 145(8):2051-2059. PubMed ID: 31270600
[TBL] [Abstract][Full Text] [Related]
17. Expression of NY-ESO-1 in Triple-Negative Breast Cancer Is Associated with Tumor-Infiltrating Lymphocytes and a Good Prognosis.
Lee HJ; Kim JY; Song IH; Park IA; Yu JH; Gong G
Oncology; 2015; 89(6):337-44. PubMed ID: 26413775
[TBL] [Abstract][Full Text] [Related]
18. High level of CXCR4 in triple-negative breast cancer specimens associated with a poor clinical outcome.
Yu S; Wang X; Liu G; Zhu X; Chen Y
Acta Med Okayama; 2013; 67(6):369-75. PubMed ID: 24356721
[TBL] [Abstract][Full Text] [Related]
19. S100A14 is a novel independent prognostic biomarker in the triple-negative breast cancer subtype.
Ehmsen S; Hansen LT; Bak M; Brasch-Andersen C; Ditzel HJ; Leth-Larsen R
Int J Cancer; 2015 Nov; 137(9):2093-103. PubMed ID: 25912829
[TBL] [Abstract][Full Text] [Related]
20. HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.
Abdel-Fatah TM; McArdle SE; Agarwal D; Moseley PM; Green AR; Ball GR; Pockley AG; Ellis IO; Rees RC; Chan SY
Clin Cancer Res; 2016 Feb; 22(4):905-14. PubMed ID: 26240276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]